Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rapid Oxygen is a private medtech company based in Connecticut that develops and markets emergency oxygen devices rather than therapeutics. Its lead and apparently sole commercial product is the R15, an FDA-cleared portable emergency oxygen device designed to deliver humidified oxygen for airway and cardiac emergencies without requiring electricity, batteries, or high-pressure oxygen cylinders. The company positions the R15 as a non-explosive, publicly accessible first-aid oxygen solution that can be deployed in homes, schools, workplaces, gyms, airports, and other public settings. Rapid Oxygen states that the technology was developed with input from the University of Michigan and is protected by patents covering oxygen production and delivery. Overall, the business is best characterized as a healthcare device company focused on emergency preparedness and first-aid oxygen access, not a drug-development biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rapid Oxygen.